IBS Self Help and Support Group Forums - IBSgroup.org: Google- Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid ... - MarketWatch (press release) - IBS Self Help and Support Group Forums - IBSgroup.org

View New Content

Latest Poll: If you suffer from a chronic pain condition (IBS or other painful condition), how do you feel about your doctor's care?

Notice:

Topics are automatically created in this forum from a mix of newsfeeds. Please be aware that we have no control over the quality or factual representation of these postings. Some may be informational, whereas some may be wholly inaccurate.

Always research all options and discuss them with your physician before following any specific directive provided in these articles.

To aid other readers, you may rate each article as you review them.

Unfortunately, we have no control over duplicate postings which represent multiple sources of the same article.

Current feeds are: Google, IBS.about.com, Medical News Today, MedicineNet, Pubmed, SmartBrief

Page 1 of 1

You cannot start a new topic
You cannot reply to this topic

Google- Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid ... - MarketWatch (press release) Rate Topic:

#1 Health Reporter

Newsfeeder

Group: RSS
Posts: 39,861
Joined: 12-February 08
Country:United States

Posted 02 February 2012 - 02:31 AM

Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid ...
MarketWatch (press release)
AMITIZA is a chloride channel activator indicated for the treatment of CIC (24 mcg twice daily) in adults and for IBS-C (8 mcg twice daily) in women 18 years of age and older. AMITIZA is contraindicated in patients with known or suspected mechanical ...

and more »

View the full article